Key facts
- Valid’s last known valuation is $29.5M (Feb 2025).
- It has raised $6.9M; the latest was Seed Round ($6.9M) in Jan 2025.
- Notable investors include Canaan Partners, Dhuna Ventures, Expansion Venture Capital, Scott Banister, J Ventures Mgmt — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Valid
- ·The full record, as it builds
Funding rounds
No funding rounds for Valid are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Valid
Developer of drug discovery funnel intended to improve predictive validity at scale. The company integrates complex, disease-relevant in-vitro models with human genetics and AI-driven data and increases the success of drug discovery by combining the predictive validity of industrial-scale advanced human pluripotent stem cell disease models with AI-enabled experimental data generation, enabling researchers with early stages of drug discovery to be cost-effective by providing insights into therapeutic targets.
- Sector
- Healthcare
- HQ
- Wayland, MA, United States
- Founded
- 2024
- Employees
- 16
- Website
- validtx.com/
- Ownership
- Privately Held (backing)
Valid doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Valid shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Valid in its N-PORT filings yet. We sweep new filings monthly.